Revised SPC: Lonsurf 20 mg/8.19 mg (trifluridine and tipiracil) film-coated Tablets

SPC now includes information on dosing, monitoring and the safety profile in patients with severe renal impairment. Details of a dedicated study evaluating pharmacokinetics in patients with advanced solid malignancies with varying degrees of renal impairment have also been added.


electronic Medicines compendium